Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632 1633 1637 1651
This examiner grants 62% of resolved cases
Jagamya NMN Vijayaraghavan is an examiner in Art Unit 1632 within Tech Center 1600. The examiner has a record of 40 resolved cases. The data shows an allowance rate of 62.5% for these applications. This 62.5% rate provides a baseline for applicants to evaluate the probability of success when their cases are assigned to this examiner. The 40 resolved cases indicate the examiner's history of examination within this technical area.
The median days to allowance for successful cases is 1363. This 1363-day figure represents the typical timeline for the prosecution process from filing to grant. An important metric in this profile is the 49.3% interview lift. This 49.3% lift shows that the likelihood of an allowance increases significantly when an interview is conducted with the examiner. Practitioners should consider the 49.3% lift as a primary reason to engage in verbal discussion to address rejections. The 1363-day median pendency and the 62.5% allowance rate are key factors for strategic planning. By leveraging the 49.3% interview lift, applicants may find a much more effective path to allowance.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18727951 | METHOD FOR EVALUATING CARDIOMYOCYTES USING RAMAN SCATTERING | Non-Final OA | National Institute of Advanced Industrial Science and Technology |
| 18547840 | Opsins as Chemosensory Receptors and Related Methods | Non-Final OA | The Regents of the University of California |
| 18298942 | SYNTHETIC TRANSCRIPTION FACTORS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18019931 | PLATFORM VECTOR FOR MODULAR AND SIMPLIFIED INSERTION OF TRANSGENES INTO ALPHAHERPESVIRINAE | Final Rejection | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. |
| 18437415 | METHODS OF PRODUCING THREE-DIMENSIONAL CELLULAR TISSUES, AND THREE-DIMENSIONAL CELLULAR TISSUES | Final Rejection | TOPPAN Inc. |
| 17572262 | TRANSCRIPTIONAL REGULATORY ELEMENT AND ITS USE IN ENHANCING THE EXPRESSION OF HETEROLOGOUS PROTEIN | Final Rejection | WuXi Biologics Ireland Limited |
| 17787161 | 3D TISSUE COMPOSITE AND METHOD OF PRODUCING 3D TISSUE COMPOSITE | Final Rejection | The University Of Tokyo |
| 18729958 | SELECTION METHOD FOR DOMESTIC ANIMAL BREEDING | Non-Final OA | THE PENN STATE RESEARCH FOUNDATION |
| 18246872 | COMPOSITIONS AND METHODS FOR TREATMENT OF FABRY DISEASE | Final Rejection | The Trustees of the University of Pennsylvania |
| 18460022 | METHODS AND COMPOSITIONS FOR GENERATING EMBRYOS IN VITRO FROM PLURIPOTENT STEM CELLS | Non-Final OA | Cambridge Enterprise Limited |
| 17796303 | Process for Making Adenoassociated Viral Vectors | Non-Final OA | Oxford University Innovation Limited |
| 18863977 | ADAPTATIONS FOR HIGH EFFICIENCY AND ALTERED PAM USAGE WITH TN7-CRISPR-CAS TRANSPOSITION SYSTEMS | Non-Final OA | Cornell University |
| 17697028 | METHODS FOR IDENTIFYING GENOMIC SAFE HARBORS | Non-Final OA | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 18019421 | METHODS OF TREATING CARDIAC DISORDERS AND CONGESTIVE HEART FAILURE AND ADMINISTERING AAV VECTORS | Final Rejection | ASKBIO INC. |
| 17779458 | METHODS FOR ACTIVATION AND EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES | Final Rejection | KSQ Therapeutics, Inc. |
| 18726666 | INTERLOCKING POROUS HYDROGEL BLOCKS | Non-Final OA | Ronawk, Inc. |
| 17617252 | TARGETED GENE EDITING CONSTRUCTS AND METHODS OF USING THE SAME | Non-Final OA | UNIVERSITAT POMPEU FABRA |
| 17897857 | PROMOTER OF THE TRANSCRIPTION OF NUCLEIC ACID SEQUENCE AN ITS USE | Non-Final OA | UNIVERSITA' DEGLI STUDI DI BARI ALDO MORO |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy